SNGX - Soligenix SERB Pharma team up to develop therapy for ricin poisoning

• Soligenix ( NASDAQ: SNGX ) said it signed an exclusive license to supply its ricin antigen to SERB Pharmaceuticals to develop a novel therapy for ricin toxin poisoning.
• There is an unmet need for protection against this highly potent toxin for which there is no vaccine or therapeutic intervention available.
• SERB will use its broad-spectrum polyclonal antibody platform, gained via the acquisition of BTG Specialty Pharmaceuticals, and the antibodies will be generated using a modified form of the ricin toxin, developed by Soligenix, the companies said in July 25 press release.
• The companies noted that specific licensing terms were not being disclosed this time, but consists of a manufacturing supply agreement and small royalty percentage upon commercialization.
• Ricin can be extracted from the seeds of the castor oil plant Ricinus communis and is one of the most toxic biological agents known, the companies noted.

For further details see: